- Home
- XEL vs ALNY Comparison
XEL vs ALNY Comparison
Compare XEL & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XEL
- ALNY
- Stock Information
- Founded
- XEL 1909
- ALNY 2002
- Country
- XEL United States
- ALNY United States
- Employees
- XEL N/A
- ALNY N/A
- Industry
- XEL Power Generation
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- XEL Utilities
- ALNY Health Care
- Exchange
- XEL Nasdaq
- ALNY Nasdaq
- Market Cap
- XEL 41.7B
- ALNY 40.4B
- IPO Year
- XEL N/A
- ALNY 2004
- Fundamental
- Price
- XEL $67.56
- ALNY $329.77
- Analyst Decision
- XEL Buy
- ALNY Strong Buy
- Analyst Count
- XEL 12
- ALNY 23
- Target Price
- XEL $75.92
- ALNY $340.00
- AVG Volume (30 Days)
- XEL 3.1M
- ALNY 811.6K
- Earning Date
- XEL 07-31-2025
- ALNY 07-31-2025
- Dividend Yield
- XEL 3.38%
- ALNY N/A
- EPS Growth
- XEL 2.18
- ALNY N/A
- EPS
- XEL 3.40
- ALNY N/A
- Revenue
- XEL $13,698,000,000.00
- ALNY $2,348,099,000.00
- Revenue This Year
- XEL $13.83
- ALNY $30.77
- Revenue Next Year
- XEL $6.50
- ALNY $30.51
- P/E Ratio
- XEL $19.86
- ALNY N/A
- Revenue Growth
- XEL N/A
- ALNY 17.21
- 52 Week Low
- XEL $51.97
- ALNY $205.87
- 52 Week High
- XEL $73.38
- ALNY $330.00
- Technical
- Relative Strength Index (RSI)
- XEL 45.91
- ALNY 68.69
- Support Level
- XEL $66.87
- ALNY $315.03
- Resistance Level
- XEL $69.00
- ALNY $327.21
- Average True Range (ATR)
- XEL 1.18
- ALNY 8.66
- MACD
- XEL 0.15
- ALNY 0.27
- Stochastic Oscillator
- XEL 60.72
- ALNY 99.33
About XEL Xcel Energy Inc.
Xcel Energy manages utilities serving 3.8 million electric customers and 2.2 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy suppliers in the US with more than half of its electricity sales coming from carbon-free energy.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.